Bristol Myers Squibb (CELG-RI) Non-Current Deffered Revenue (2009 - 2019)

Bristol Myers Squibb has disclosed Non-Current Deffered Revenue across 11 years of filings, most recently posting $448.0 million for Q1 2019.

• In Q1 2019, Non-Current Deffered Revenue changed 0.22% year-over-year to $448.0 million; the TTM figure through Mar 2019 stood at $448.0 million (changed 0.22% YoY), while the FY2018 annual figure was $468.0 million, up 3.08% from the prior year.
• Non-Current Deffered Revenue eased to $448.0 million in Q1 2019, from $468.0 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for CELG-RI reached as high as $697.0 million in Q1 2015 and fell as low as $447.0 million in Q1 2018.
• The 5-year median for Non-Current Deffered Revenue is $528.0 million (2017), against an average of $542.5 million.
• Annual changes were most pronounced in 2015 — Non-Current Deffered Revenue tumbled 35.99% — and 2018, when it rose 3.08%.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $586.0 million in 2015, then declined by 6.66% to $547.0 million in 2016, then dropped by 17.0% to $454.0 million in 2017, then rose by 3.08% to $468.0 million in 2018, then dropped by 4.27% to $448.0 million in 2019.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $448.0 million, $468.0 million, and $486.0 million for Q1 2019, Q4 2018, and Q3 2018 respectively.